Leading specialists in iron deficiency convene at the largest global multi-disciplinary educational event dedicated to the topic (3rd European Iron Academy)
The 3rd European Iron Academy (EIA) will take place on the 12th and 13th September 2016 in Berlin, Germany, and will bring together over 450 clinicians with an interest in iron deficiency. Iron deficiency is the most common nutritional disorder in the world and is the leading cause of anaemia2. The condition occurs frequently across multiple therapeutic areas e.g. in patients with chronic diseases such as inflammatory bowel disease, heart failure and chronic kidney disease3. In such conditions, inadequately managed iron deficiency has been associated with poor patient outcomes, including increased hospitalisations, reduced quality of life and even higher mortality rates4-7.
The 3rd EIA has the goal of further raising awareness of iron deficiency and stimulating discussion amongst peers, helping them to better understand the causes, the need for improved diagnosis and the current treatment options for their patients. The 2016 programme offers delegates the opportunity to tailor the sessions to their own clinical interests/areas of expertise; engage in interactive patient case scenarios and breakout sessions; and discuss current standards in iron deficiency management with experts in Q&A-style sessions. The 3rd EIA is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide participants with CME credits, and is supported by an educational grant from Vifor Pharma.
“We are delighted to be running the 3rd European Iron Academy this year, which specifically addresses the need for continuing medical education on iron deficiency,” said Professor Stefan Anker (Germany), EIA 2016 co-Chair and Professor of Innovative Clinical Trials at the University Medical Center Göttingen, Germany. “This year’s programme will review the latest data relating to the diagnosis and treatment of iron deficiency within a number of key therapy areas, including cardiology, gastroenterology, nephrology and haematology.”
The EIA will use an all-encompassing approach to education and to improving patient outcomes in many disease areas.
About the European Iron Academy
The European Iron Academy is an independent educational event developed and organised by a Steering Committee of international experts in iron deficiency and iron deficiency anaemia, which will bring together medical specialists with the aim of achieving the following objectives related to the topic:
- Convey the latest knowledge in iron deficiency and iron deficiency anaemia
- Discuss safety and best practice in the treatment
- Discuss the global burden, prevalence and real-world impact across different specialties
- Share practical clinical experiences across different specialities and treatment settings
This year’s EIA will build on the successes of previous Iron Academy meetings, which were annually held at the national-level in Switzerland since 2008, and the 2nd EIA, held in Paris in March 2015. For more information about this year’s EIA and the previous two meetings, please visit: http://europeanironacademy.org/
About Vifor Pharma
Vifor Pharma, a company of the Galenica Group, is a world leader in the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency. The company also offers a diversified portfolio of prescription medicines as well as over-the-counter (OTC) products. Vifor Pharma, headquartered in Zurich, Switzerland, has an increasingly global presence and a broad network of affiliates and partners around the world. For more information about Vifor Pharma, please visit www.viforpharma.com.
1. Unicef http://www.unicef.org/nutrition/23964_iron.html Last accessed: 10 November 2014
2. Kassebaum J. The Global Burden of Anemia. Hematol Oncol Clin N Am. 30, 247–308, doi:10.1016/j.hoc.2015.11.002 (2016).
3. Donovan, A., Roy, C. N. & Andrews, N. C. The ins and outs of iron homeostasis. Physiology 21, 115-123, doi:10.1152/physiol.00052.2005 (2006).
4. Lopez, A et al. Iron deficiency anaemia. The Lancet. 27, 387(10021), doi: 10.1016/S0140-6736(15)60865-0 (2016).
5. Koduru, P & Abraham, BP The role of ferric carboxymaltose in the treatment of iron deficiency anemia in patients with gastrointestinal diseases. Therapeutic advances in Gastroenterology. 9, 76–85, doi:10.1177/1756283X15616577 (2016).
6. Jankowska, EA et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. European Journal of Heart Failure. 18, 786-95, doi:10.1002/ejhf.473 (2016).
7. Nuñez, J et al. Iron deficiency and risk of early readmission following a hospitalization for acute heart failure. European Journal of Heart Failure. 18, 798-802, doi:10.1002/ejhf.513 (2016).
Madano for European Iron Academy
Dr Reghu Venkatesan
Telephone: +44 (0)20 3595 2590
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Elliott Advisors (UK) Limited Statement on Telecom Italia23.3.2018 07:00 | Pressemelding
Given the momentum behind Elliott's campaign at Telecom Italia to improve both performance and governance, Elliott was not surprised to see yesterday's resignation of seven board members affiliated with Vivendi. Unable to advance any meritorious arguments, the Board has simply abandoned their posts to stall for time. Elliott regards this action as cynical and self-serving, in that it delays the ability of Telecom Italia shareholders to express their votes at the upcoming AGM. This is yet another example of minority shareholder rights at Telecom Italia being abrogated and the continued disregard of corporate governance best practice. Finally, Vivendi should note Elliott's forty-year track record of consistent value creation, and sustained, long-term commitments to expose poor governance and catalyse positive change; Elliott's investment history in Telecom Italia dates back to 1999, well before Vivendi became a shareholder in the Company. About Elliott Elliott Management Corporation mana
Smiths Detection Hold Baggage Scanner Meets Highest Security Standards in EU23.3.2018 07:00 | Pressemelding
The Smiths Detection HI-SCAN 10080 XCT has achieved ECAC approval as a Standard 3.1 explosives detection system for hold baggage – the highest, defined security standard in the EU. This significant advance was made possible by using a dual-view, dual-energy line scanner with high resolution 3D Computed Tomography (CT) to deliver exceptional data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005050/en/ Smiths Detection HI-SCAN 10080 XCT (Graphic: Business Wire) This achievement gives airports currently upgrading to Standard 3 technology, the option to increase detection levels even further to 3.1; and any standard 3 systems already installed can be easily elevated to 3.1 via a software upgrade. The detection algorithms are interchangeable on a bag by bag basis depending on the destination and associated risk level. This offers additional flexibility and productivity. “With the capability to meet detection requirements
Sofinnova Partners Leads SafeHeal’s €6 Million Series a Financing Round23.3.2018 07:00 | Pressemelding
SafeHeal, an early-stage medtech company specialized in digestive surgery and focused on the development of the Colovac device, announces today that it has closed a €6 million Series A financing round led by Sofinnova Partners. Based in Paris, SafeHeal develops an innovative digestive anastomosis protection device, called Colovac, designed to reduce complications and obviate the need for ostomies for colectomy patients. This technology consists of a minimally invasive and fully reversible implant that remains in place until the body’s natural healing and tissue repair processes are complete, for approximately two weeks, after which it is removed. SafeHeal’s device has the potential to radically transform the market while significantly improve patients’ quality of life by enabling them to resume their normal life without having to bear an artificial anus and wear ostomy pouches for several months. About 270,000 colectomy patients receive an ostomy every year in Europe and the USA, repre
Ipsen Receives Positive CHMP Opinion for Cabometyx® (cabozantinib) for the First-Line Treatment of Adults with Intermediate- or Poor- Risk Advanced Renal Cell Carcinoma23.3.2018 06:00 | Pressemelding
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA) provided a positive opinion for Cabometyx® (cabozantinib) 20, 40, 60 mg for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma (aRCC).The CHMP positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU). Alexandre Lebeaut, Executive Vice President, R&D and Chief Scientific Officer said: “Today’s positive opinion from the CHMP is important news for patients with previously untreated advanced renal cell carcinoma, who can shortly benefit from Cabometyx ® as a new first-line treatment option. Following the evidence of its clinical value after a prior VEGF-targeted treatment, we are pleased to be able to expand the benefit of Cabometyx ® for treatment-naïve patients wit
Swiss Wearable Brand MyKronoz Breaks Worldwide Records with its Hybrid Smartwatch ZeTime, on the Sidelines of a Challenging Baselworld 201822.3.2018 16:32 | Pressemelding
On the sidelines of a downsized Baselworld 2018, MyKronoz, the premier watchmaking brand of the smart generation today announces record-breaking crowdfunding results of its hybrid smartwatch ZeTime, with more than $8,000,000 raised in less than a year. The international success of its unique and groundbreaking flagship wearable is followed by the release of a new digital video campaign “I’m a watch; I’m a smartwatch”. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180322005963/en/ MyKronoz ZeTime Petite & Regular top $8M in crowdfunding (Photo: Business Wire) After a historic 35-days Kickstarter campaign launched in March 2017, ZeTime has pursued, since then, its crowdfunding journey on a variety of international and local platforms: Indiegogo, Makuake in Japan, Zec Zec in Taïwan, Wadiz in Korea and on the leading chinese e-commerce website JD.com. Further to this online momentum, MyKronoz has successfully shipped to over 10
Redwood Software Announces First Industry Robotic Licensing Model to Revolutionize Transparent Marketplace Pricing22.3.2018 14:59 | Pressemelding
Redwood Software, the pioneer behind ‘The Robotic Enterprise’, today announced the launch of a revolutionary new robotic licensing model, where customers only pay for the robotic services they consume within their business. Available now, this new licensing model allows customers to directly compare the costs of manual work against processes that are robotized. With the unique Robotic Service Charge, Redwood only charges for the delivery of a robotic service, equivalent to a unit of work that can done by a person (send an email, download a report, reconcile two reports etc.). Redwood delivers a catalogue of 35,000 of these ready built robotic services that can be linked together by business users in a visual plug and play interface. End-to-end business processes can be modelled, robotized, tested and deployed without cost and risk. Only when the robotic service is consumed is a charge made, always replacing work that would otherwise be done manually. Within the Robotic Service Charge,